St. Joseph's Healthcare Hamilton

Theralase Technologies launches new clinical study site at St. Joseph's Healthcare Hamilton for its bladder cancer therapy. Phase II study results show 61.9% Complete Response (CR), increasing to 68.3% with Indeterminate Response; 43.6% of CR patients maintained response for 12 months. The study reported 100% safety with no serious adverse events. Theralase operates 11 clinical sites across North America, with 4 more planned for Q4 2024/Q1 2025. The company seeks partnering opportunities for international commercialization of Ruvidar™, targeting regulatory approval in 2026.